Compare Davita Inc (DVA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Msci Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Msci Inc trades at $562.19 (market cap $40.38B). The key difference: Msci Inc is far larger — about 3.6× Davita Inc's market cap, and Msci Inc pays a 1.48% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Msci Inc for 82 Days on average.
| DVA | MSCI | |
|---|---|---|
Market Cap | $11.28B | $40.38B |
Volume | 650,294 | 414,140 |
Sector | Health | Financials |
52-Week High | $240.96 | $643.83 |
52-Week Low | $103.87 | $511.84 |
Typical Hold Time | 113 Days | 82 Days |
Enterprise Value | $24.00B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
MSCI trades at $555.38, up 0.08% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $3.13B and net income margin of 40.73%. Recent Q2 2026 earnings slightly missed expectations at $4.94 EPS versus $4.99 expected, though Q1 and Q4 2025 beat estimates. Analyst consensus remains strongly bullish with 74% buy ratings and $701.71 price target, representing 26% upside potential. The stock shows consistent revenue growth from $2.2B in 2022 to $3.1B in 2025.
MSCI presents a compelling investment case with premium valuation (P/E 30.37) justified by strong profitability and market leadership. Key risks include high debt levels ($4.51B long-term debt) and competitive pressures in financial data services. The upcoming Q3 2026 earnings report on October 20, 2026, will be crucial for validating growth trajectory. Institutional sentiment remains positive given the company's recurring revenue model and expansion into climate risk analytics through the First Street acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
